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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with cases
of either familial or sporadic origin. Several polymorphisms in a number of genes have been
proved to have an important role in the development of PD. Particular attention has recently
been  paid  to  genes  of   the  glucocerebrosidase  (GBA)  and  the  vacuolar  protein  sorting-
associated protein 35 (VPS35).
In this study, the three most common mutations (L444P, N370S and R120W) of the GBA gene
and  the  D620N mutation  of  the  VPS35  gene  were  examined  in  124  Hungarian  patients
diagnosed with sporadic PD (SPD) and 122 control subjects. 
The frequency of the L444P mutation of the GBA gene proved to be higher in the PD patients
(2.4%) than in the controls (0%), although the difference was not statistically significant. All
the  patients  who  carried  the  mutant  allele  were  in  the  early-onset  PD  (EOPD)  group.
However, neither the R120W nor the N370S variant of the GBA gene nor D620N mutation of
the VPS35 gene were detected among the PD cases or the controls.
Even though these results suggest that the studied mutations are quite rare in SPD patients, the
most frequent L444P mutation of the GBA gene may be associated with the development of
EOPD in the Hungarian population.
Keywords
Parkinson’s disease, GBA mutations, L444P, VPS35 mutation
Introduction
The most prominent neuropathological features of Parkinson’s disease (PD), the second most
common neurodegenerative disorder, are the loss of dopaminergic neurons in the substantia
nigra pars compacta and the presence of Lewy bodies, although the precise pathomechanism
is still  not fully understood. Gene–environment interactions are certainly implicated in the
multifactorial pathogenesis of PD [6].
The majority of PD cases are sporadic; only 15-20% of the cases are identified as familial. In
the background of these familial cases, numerous mutations have been identified in several
genes  that  cause  autosomal  dominant  (PARK1,  PARK3,  PARK4,  PARK5,  PARK8  and
PARK11) or autosomal recessive (PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15)
forms of PD [9]. The D620N mutation in the vacuolar protein sorting-associated protein  35
(VPS35) was recently discovered as a new cause of PD [12]. Furthermore, genetic risk factors
have  been  identified  in  sporadic  forms  of  PD  (SPD)  [9].  The  gene  coding  for
glucocerebrosidase (GBA) has been reported to have a potential role in the development of
PD [5].
Gaucher’s  disease  (GD)  is  an  autosomal  recessively inherited  glycolipid  storage  disorder
caused  by a  deficiency of  the  lysosomal  enzyme  GBA.  Several  studies  have  reported  a
clinical, neuropathological or genetic association between GD and PD [5, 8, 20].
The GBA gene is  localized at  chromosome 1q21 and has  more than 300 mutations  [16].
Numerous  genotyping  studies  have  demonstrated  associations  between  several  GBA
mutations  and  PD  in  different  ethnic  groups.  As  an  example,  the  frequencies  of  GBA
mutations  in  PD patients  were  highest  amongst  Ashkenazi  Jews  (ranging from 13.7% to
31.3%) [1, 7, 13]. Furthermore, several studies have indicated that a high frequency of GBA
mutations is  related  to  an increased  risk of  PD amongst  Japanese,  Canadian,  Portuguese,
Greek, Norwegian, Italian, Serbian and Chinese populations [4, 11, 18, 25, 26, 28, 35, 38, 41].
N370S has been demonstrated to be the most common mutation among  Ashkenazi Jewish PD
patients (14.1%), and it is also the most frequent mutation in several European (e.g. Serbian
(1.9%), French (2.9%) and Portuguese (2.2%)) populations [4, 18, 20, 32]. A Japanese study
detected a significant association between the R120W mutation and PD [25]. L444P is the
most  common  variant  among  non-Ashkenazi  Jewish  patients.  The  possible  association
between this mutation and PD has been investigated in a number of studies [23, 38, 39, 41].
The VPS35 gene, which is involved in the development of many neurodegenerative diseases,
including Alzheimer’s disease and PD [12, 33], is localized to 16q11.2, and various mutations
have been reported in it [40]. The VPS35 protein is a key component of the retromer complex
which  mediates  the  retrograde  transport  of  proteins  from  endosomes  to  the  trans-Golgi
network [3]. Amongst the mutations of the VPS35 gene, the D620N missense mutation has
been reported to be pathogenic for PD [37, 42], mainly in the autosomal dominantly inherited
cases, but it has additionally been detected in some sporadic PD cases [2, 19, 21, 31, 37, 42].
A recent multicentre study determined the frequencies of VPS35 mutations in PD in various
populations.  The D620N mutation  was found in 5 familial  and 2 sporadic cases  [30].  In
contrast,  other  studies  suggest  that  there  is  no  such  mutation  in  SPD  in  the  Caucasian
population [19, 31].
No study has been conducted previously to assess the frequency of GBA or VPS35 gene
mutations in Hungarian PD patients. The aim of the current preliminary study was therefore to
investigate whether any of the L444P, N370S and R120W mutations of the GBA gene or the
D620N mutation of the VPS35 gene is present in SPD in the Hungarian population, which
belongs in the Caucasian race.
Material and methods
Subjects
124 SPD patients (mean age: 66.5 ± 9.5 years) were enrolled in the study. The mean age at
onset of PD was 59.1 ± 10.9 years. Early-onset PD (EOPD) was defined as an age at onset ≤
60 years (67 subjects) and late-onset PD (LOPD) as an age at onset > 60 years (57 subjects).
All  of  the  patients  were  examined by movement  disorder  specialists,  who confirmed the
diagnosis of SPD. Secondary forms of parkinsonism were excluded. The PARK2 and PARK8
mutations were not present in the assessed patient population.
The control group comprised 122 volunteer individuals (mean age: 64.3 ± 8.2 years) who had
no history of neurological or psychiatric disorders (Table 1). All the patients with SPD and all
the controls were of Hungarian origin and were enrolled in the Department of Neurology at
the University of Szeged.
The study protocol was approved by the Medical Research Council Scientific and Research
Ethics  Committee  (47066-3/2013/EKU  (556/2013))  and  all  study  participants  gave  their
written informed consent in accordance with the Helsinki Declaration.
Table 1.
Characteristics of groups of PD patients and controls
PD group Control group 
No. 124 122
Age (years, mean ± SD) 66.5 ± 9.5 64.3 ± 8.2
Age at onset ≤ 60 years 67 (54%)
Age at onset > 60 years 57 (46%)
DNA isolation
Genomic DNA was extracted from peripheral blood by a standard desalting method [24], and
stored at –20 °C until further use.
Analysis of GBA mutations
The L444P, R120W and N370S polymorphisms of the GBA gene were determined in all the
patients and the controls by using the polymerase chain reaction and restriction fragment-
length polymorphism (PCR-RFLP) techniques. Three previously described primer pairs were
used separately to  amplify the  DNA region of  each mutation  [1,  39].  The PCR primers,
annealing temperatures, restriction enzymes and fragment lengths are listed in Table 2. The
digested products were separated by agarose gel electrophoresis.
Place of Table 2
Detection of VPS35 mutation
The D620N mutation in the VPS35 gene was determined by PCR-RFLP. The PCR conditions
and primers were as described previously [34]. The PCR products were digested with the
HinFI restriction enzyme (Thermo Scientific, Waltham, MA, USA) at 37 °C for 30 min. The
digested products were separated by agarose gel electrophoresis. The genotypes were defined
as GG (257 bp, 231 bp, 139 bp, 74 bp, 18 bp), GA (257 bp, 231 bp, 213 bp, 139 bp, 74 bp, 18
bp) or AA (257 bp, 231 bp, 213 bp, 18 bp).
Statistical analysis
SPSS software  version  22.0  was  applied  for  the  evaluation  of  the  data  populations.  The
genotype frequencies in the patients and the controls were analysed by using the Fisher exact
test. The normality of the data was checked with the Kolmogorov-Smirnov test. Since the data
exhibited Gaussian distribution, and the Levene test did not reveal significant differences in
the homogeneity of variances, we applied the independent  t  test for the comparison of the
difference  in  age  between  the  PD  groups  and  the  controls.  Odds  ratio  (OR)  and  95%
confidence intervals (95% CI) were calculated to test for an association between the GBA
mutation and PD. A p value of less than 0.05 was considered statistically significant. 
Results
GBA gene mutations
Among the PD patients, 3 individuals (2.4%) carried a heterozygous mutant GBA allele: in all
3 cases the L444P substitution. In contrast, no mutations were detected in the control group.
The difference in mutation frequencies between the patients (2.4%) and controls (0%) was not
statistically significant (p = 0.247). However, the carriers of the GBA mutation were at an
increased risk of developing PD (OR = 6.05, 95% CI 0.300 to 122.06). Moreover, all the
patients  who  carried  the  mutant  allele  were  in  the  EOPD  group.  The  frequency  was
significantly  higher  in  the  EOPD  group  than  in  the  controls  (p=0.042).  However,  a
comparison of the frequency between the EOPD group and the LOPD group failed to reveal
any difference (p = 0.247).
Neither  the  R120W nor  the  N370S  variant  of  the  GBA gene  was  identified  among  the
assessed PD cases and controls.
VPS35 gene mutation
The common VPS35 D620N mutation was not detected either in the PD patients or in the
controls in the assessed population.
Discussion
PD  is  a  heterogeneous  disorder.  The  majority  of  PD  cases  (75-80%)  are  sporadic;  the
remaining  15-20% of  the  patients  have  a  familial  history.  Sporadic  PD may result  from
complex interactions between genomic and environmental factors. Genome-wide association
studies (GWAS) are carried out to identify rare genetic variants that increase the risk of PD.
Multiple GWAS on PD patients and controls have revealed numerous loci, including GBA
and MAPT, as risk factors for sporadic PD [36].
Moreover, several genes (PARK1-18) have been identified that can cause autosomal dominant
or autosomal recessive forms of PD [17]. They include some genes which play an important
role in the pathogenesis of SPD [10,  22]. The D620N mutation in VPS35 (PARK17) was
recently discovered as a  new cause of PD, mainly in the autosomal dominantly inherited
cases, although it may additionally have a role in SPD, but the results are inconsistent [37,
42].
In the present study, we examined the three common mutations (L444P, N370S and R120W)
of the GBA gene and the D620N mutation of the VPS35 gene in the Hungarian population
(124 patients with SPD and 122 controls). 
Several studies have reported that the frequencies of GBA mutations are higher in PD patients
(5-10%) than in controls, but the range varies in different ethnic groups [29]. Our results
indicated that the PD patients demonstrated a higher frequency (2.4%) of the L444P mutation
of  the  GBA gene  as  compared  with  the  controls  (0%),  although  the  difference  was  not
significant. This finding is similar to those of previous studies that have reported associations
between the L444P mutation and PD [23, 38, 39]. The L444P mutation was shown to occur
with incidences of 2%, 1.39% and 1.14% among American non-Jewish, Canadian and British
PD patients, respectively [8, 27, 28]. Moreover, an Eastern Canadian study concluded that the
frequency of L444P was higher among PD patients  (3.1%) than among controls [15]. 
A number of studies have found that GBA mutations may be considered a risk factor, mainly
in EOPD cases [8,  14,  39]. Our study revealed that all the patients who carried the mutant
allele were in the EOPD group. These data emphasized the significance of the GBA mutation,
particularly in EOPD cases.
Besides the L444P mutation, the other two most frequent mutations in non-Ashkenazi Jewish
patients are N370S and R120W [32], and we therefore investigated these two GBA mutations
too. We did not detect either the R120W or the N370S variant of the GBA gene among the PD
cases  or  the  controls,  although  the  N370S  mutation  was  earlier  demonstrated  in  some
European PD patients [18, 26, 32]. These diverse data suggest that the Caucasian population
is not homogeneous in this respect.
Mutations in the VPS35 gene have been identified as a causative factor of the development of
PD.  The  mutation  carriers  have  been  estimated  to  account  for  less  than  1% of  the  PD
population [19]. These mutations have been examined in a number of Caucasian populations,
with different results [19,  30,  31,  37]. We therefore investigated the presence of the D620N
mutation of the VPS35 gene in SPD patients, but we were unable to identify this mutation in
any of the patients or controls. This suggests that the D620N mutation of the VPS35 gene is at
best a rare cause of SPD.
The differences  between  the  results  of  the  various  studies  might  stem from the  different
sample  size  and  the  different  study  populations  with  the  possibility  of  certain  ethnic
variations.
The genetic causes and risk factors of PD may serve as important tools through which to
attain a better understanding of the pathomechanism. Since a genetic background is presumed
in the development of SPD in some cases, it is important to investigate the different genetic
factors in the various SPD populations, which may permit the development of new therapeutic
targets. Furthermore, the identification of novel genetic risk factors may facilitate a better
selection of homogeneous subpopulations for therapeutic studies.
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Table 2.
Primers, PCR conditions and restriction enzymes used for the detection of GBA mutations
Mutatio
n Primer sequence
Annealing
temperature
(ºC)
Restriction
enzyme
PCR
(bp)
Wild
type
(bp)
Mutant
(bp)
L444P
F: 5’-GGAGGACCCAATTGGGTGCGT-3’
R: 5’-ACGCTGTCTTCAGCCCACTTC-3’
59 NciI 637 637 535, 102
R120W
F: 5’-GCAGAGTCCCATACTCTCCT-3’
R: 5’-TGGGTGACAGAGAGAGAGACT-3’
56 NciI 836 454,300, 82 536, 300
N370S
F: 5’-GCCTTTGTCCTTACCCTC†G-3’
R: 5’-GACAAAGTTACGCACCCAA-3’
53 XhoI 105 105 89, 16
† A mismatch was introduced in the primer at one nucleotide to create a restriction site.
